Scinai Immunotherapeutics Beheer

Beheer criteriumcontroles 3/4

De CEO Scinai Immunotherapeutics is Amir Reichman, benoemd in Mar2021, heeft een ambtstermijn van 3.67 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 927.00K, bestaande uit 56.1% salaris en 43.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.29% van de aandelen van het bedrijf, ter waarde $ 7.25K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.4 jaar en 4.7 jaar.

Belangrijke informatie

Amir Reichman

Algemeen directeur

US$927.0k

Totale compensatie

Percentage CEO-salaris	56.1%
Dienstverband CEO	3.7yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	4.4yrs
Gemiddelde ambtstermijn bestuur	4.7yrs

Recente managementupdates

Recent updates

Here's Why BiondVax Pharmaceuticals (NASDAQ:BVXV) Can Afford Some Debt

Nov 10

Bionvax Pharmaceuticals GAAP EPS of -NIS0.02

Aug 25

BiondVax, European Investment Bank agree on new terms to co's outstanding €24M loan

Aug 10

We Think BiondVax Pharmaceuticals (NASDAQ:BVXV) Has A Fair Chunk Of Debt

Mar 31

BiondVax Pharmaceuticals under pressure on pricing $12.1M ADSs follow-on offering

Jan 29

Analyse CEO-vergoeding

Hoe is Amir Reichman's beloning veranderd ten opzichte van Scinai Immunotherapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$4m
Mar 31 2024	n/a	n/a	-US$5m
Dec 31 2023	US$927k	US$520k	-US$6m
Sep 30 2023	n/a	n/a	-US$9m
Jun 30 2023	n/a	n/a	-US$8m
Mar 31 2023	n/a	n/a	-US$7m
Dec 31 2022	US$1m	US$368k	-US$6m
Sep 30 2022	n/a	n/a	-US$8m
Jun 30 2022	n/a	n/a	-US$8m
Mar 31 2022	n/a	n/a	-US$8m
Dec 31 2021	US$1m	US$664k	-US$8m

Compensatie versus markt: De totale vergoeding ($USD 927.00K ) Amir } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 650.80K ).

Compensatie versus inkomsten: De vergoeding van Amir is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Amir Reichman (48 yo)

3.7yrs

Tenure

US$927,000

Compensatie

Mr. Amir Reichman M.Sc, M.B.A, has been the Chief Executive Officer at Scinai Immunotherapeutics Ltd. (formerly known as BiondVax Pharmaceuticals Ltd.) since March 02, 2021 and has been its Director since...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Amir Reichman	CEO & Director	3.7yrs	US$927.00k	0.29% $ 7.2k
Uri Ben-Or	Chief Financial Officer	17.8yrs	US$174.00k	geen gegevens
Elad Mark	Chief Operating Officer	5.2yrs	US$265.00k	geen gegevens
Dalit Fischer	Chief Technology Officer	less than a year	US$232.00k	geen gegevens
Tamar Ben-Yedidia	Chief Scientist	20.8yrs	US$297.00k	geen gegevens
Liat Halpert	Head of Business Development & Sales	less than a year	geen gegevens	geen gegevens
Merav Kamensky	Head of Quality Control	no data	geen gegevens	geen gegevens

4.4yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SCNI wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Amir Reichman	CEO & Director	3.8yrs	US$927.00k	0.29% $ 7.2k
Adi Raviv	Independent Director	4.7yrs	US$92.19k	0.0039% $ 99.8
Morris Laster	Independent Director	7yrs	US$78.79k	0.0039% $ 99.8
Yael Margolin	Independent Director	4.7yrs	US$87.02k	0.0039% $ 99.8
Mark Germain	Chairman of the Board	6.4yrs	US$336.67k	geen gegevens
Ruth Arnon	Head of Scientific Advisory Board	no data	geen gegevens	geen gegevens
George Lowell	Member of Scientific Advisory Board	no data	US$68.36k	0.013% $ 317.1
Avner Rotman	Independent Director	2.8yrs	US$76.59k	0.0081% $ 205.4
Michel Revel	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Samuel Moed	Director	4.7yrs	US$493.15k	geen gegevens
Jay Green	Independent Director	2.9yrs	US$72.36k	0.0025% $ 63.3
Matthias Dobbelstein	Member of Scientific Advisory Board	1.9yrs	geen gegevens	geen gegevens

4.7yrs

Gemiddelde duur

71yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SCNI wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.7 jaar).

Scinai Immunotherapeutics Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Scinai Immunotherapeutics Ltd., Annual General Meeting, Nov 21, 2024

Scinai Immunotherapeutics Ltd. Appoints Liat Halpert as Head of Business Development and Sales

BiondVax Pharmaceuticals Ltd., Annual General Meeting, Aug 24, 2023

BiondVax Pharmaceuticals Ltd. Appoints Dr. med. Matthias Dobbelstein as Member its Scientific Advisory Board

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Scinai Immunotherapeutics Ltd., Annual General Meeting, Nov 21, 2024

Scinai Immunotherapeutics Regains Full Compliance with Nasdaq Listing Requirements

Scinai Immunotherapeutics Ltd. announced that it expects to receive $2 million in funding

Scinai Immunotherapeutics on Track to Regain Nasdaq Compliance by August 23

New major risk - Shareholder dilution

Scinai Immunotherapeutics Ltd. Announces Promising Results in an In-Vivo Proof-Of-Concept Psoriatic Human Skin Model

Nasdaq Hearings Panel Determines to Grant Extension to Scinai Immunotherapeutics to Regain Compliance with Continued Listing Requirements

Scinai Immunotherapeutics Ltd. Provides Earnings Guidance for 2024

Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal

Scinai Immunotherapeutics Ltd. announced delayed 20-F filing

Scinai Immunotherapeutics Ltd. Appoints Liat Halpert as Head of Business Development and Sales

Scinai Immunotherapeutics Ltd. announced that it has received $1.694259 million in funding

Scinai Immunotherapeutics Regains Compliance with Stockholders' Equity Rule

Scinai Immunotherapeutics Ltd. Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting Its New CDMO Business Unit

Scinai Immunotherapeutics Ltd. Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting Its New CDMO Business Unit

Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance

Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance

New minor risk - Share price stability

Scinai Immunotherapeutics Ltd. announced that it has received $1.329254 million in funding

Scinai Immunotherapeutics Ltd. has completed a Follow-on Equity Offering in the amount of $1.329254 million.

Scinai Immunotherapeutics Ltd. has completed a Follow-on Equity Offering in the amount of $1.329254 million.

New major risk - Financial position

Nasdaq Grants BiondVax Pharmaceuticals Extension to Regain Compliance with Listing Rules

BiondVax Pharmaceuticals Ltd., Annual General Meeting, Aug 24, 2023

New minor risk - Share price stability

Price target increased by 10% to US$70.00

BiondVax Pharmaceuticals Receives Deficiency Letter from Nasdaq Regarding Minimum Stockholders' Equity Requirement

Biondvax Pharmaceuticals Ltd. Announces Additional Results in Preclinical Proof-of-Concept Study of its Innovative Inhaled NanoAb COVID-19 Drug

BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study

BiondVax Regains Nasdaq Compliance

BiondVax Pharmaceuticals Ltd. Appoints Dr. med. Matthias Dobbelstein as Member its Scientific Advisory Board

BiondVax Pharmaceuticals Ltd. Reports Successful Results in Preclinical in Vivo Study of its Innovative Inhaled COVID-19 NanoAb Therapy

Less than half of directors are independent

Here's Why BiondVax Pharmaceuticals (NASDAQ:BVXV) Can Afford Some Debt

BiondVax Provides Plan to Address Nasdaq Compliance

Bionvax Pharmaceuticals GAAP EPS of -NIS0.02

BiondVax, European Investment Bank agree on new terms to co's outstanding €24M loan

BiondVax Pharmaceuticals Ltd. Receives Supportive Scientific Advice from the Paul Ehrlich Institute for Covid-19 Nanoab Development Plans Including First-In-Human Phase 1/2A Safety and Efficacy Clinical Trial

Price target decreased to US$9.50

Less than half of directors are independent

BiondVax Pharmaceuticals Ltd., Annual General Meeting, May 16, 2022

We Think BiondVax Pharmaceuticals (NASDAQ:BVXV) Has A Fair Chunk Of Debt

Investor sentiment deteriorated over the past week

Less than half of directors are independent

BiondVax Pharmaceuticals Ltd. announced delayed 20-F filing

Biondvax Pharmaceuticals Ltd. Announces Resignation of Ron Babecoff from the Board of Directors Effective March 8, 2021

Biondvax Pharmaceuticals Ltd. Appoints Amir Reichman as Member to Its Board of Directors

BiondVax Pharmaceuticals Ltd. has completed a Follow-on Equity Offering in the amount of $12.052176 million.

BiondVax Pharmaceuticals under pressure on pricing $12.1M ADSs follow-on offering

BiondVax Pharmaceuticals Ltd. Announces Executive Changes, Effective March 2, 2021

New 90-day high: US$5.95

New 90-day low: US$5.20

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd